MeiraGTx Holdings Inked A Asset Purchase Agreement With Janssen Pharmaceuticals For Acquiring Remaining Stake In Botaretigene Sparoparvovec (Bota-vec) For The Treatment Of X-linked Retinitis Pigmentosa (XLRP) For $415M

12/21/23 7:05:03 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $MGTX alert in real time by email

Get the next $MGTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MGTX

Date	Price Target	Rating	Analyst
7/31/2024	$36.00	Buy	Chardan Capital Markets

More analyst ratings

$MGTX
Press Releases

Fastest customizable press release news feed in the world

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
11/24/24 7:27:00 PM ET
$LIAN
$MGTX
$OLMA
$TLPH
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including AAV-AIPL1 Agreed on pathway with MHRA for Marketing Authorization Application (MAA) under exceptional circumstances for AAV-AIPL1 for the treatment of Leber congenital amaurosis (LCA4) retinal dystrophy without further clinical studies Announced positive data from randomized, sham-controlled clinical bridging study of AAV-GAD for the treatment of Parkinson's disease LONDON and NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced
11/13/24 8:00:00 AM ET
$MGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
LONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress, which is being held from October 22-25, 2024, in Rome, Italy. The posters are available on the Posters and Publications page of the Company's website. The details of the poster presentations are as follows: Poster Number: P0015Abstract Title: Evolution of a high-producing, modular upstream platform for AAV manufacturingPoster Session III: Tuesday 22 October from 19:30 to 21:00 CESTAbstract:The
10/22/24 8:00:00 AM ET
$MGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$MGTX
Leadership Updates

Live Leadership Updates

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
11/24/24 7:27:00 PM ET
$LIAN
$MGTX
$OLMA
$TLPH
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Landsdowne Labs Names Bryan Laulicht CEO
Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design
6/13/23 9:05:00 AM ET
$MGTX
$AMAG
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Major Pharmaceuticals
MeiraGTx Appoints Debra Yu, MD to Board of Directors
LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen
4/27/22 8:00:00 AM ET
$MGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te
6/27/23 7:30:00 AM ET
$MGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023
LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for
6/22/23 4:01:00 PM ET
$MGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin
12/13/22 7:30:00 AM ET
$MGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

MeiraGTx Holdings Inked A Asset Purchase Agreement With Janssen Pharmaceuticals For Acquiring Remaining Stake In Botaretigene Sparoparvovec (Bota-vec) For The Treatment Of X-linked Retinitis Pigmentosa (XLRP) For $415M

Chat with this insight

Recent Analyst Ratings for $MGTX

$MGTX Press Releases

Fastest customizable press release news feed in the world

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

$MGTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

$MGTX Leadership Updates

Live Leadership Updates

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Landsdowne Labs Names Bryan Laulicht CEO

MeiraGTx Appoints Debra Yu, MD to Board of Directors

$MGTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

New insider Sanofi claimed ownership of 12,197,737 units of Ordinary Shares (SEC Form 3)

SEC Form 4 filed by Perceptive Advisors Llc

$MGTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

$MGTX SEC Filings

SEC Form 10-Q filed by MeiraGTx Holdings plc

MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

MeiraGTx Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$MGTX Financials

Live finance-specific insights

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

$MGTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

$MGTX Market Insights

Live Market Insights

Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose

MeiraGTx Hldgs Q1 EPS $(0.32) Beats $(0.50) Estimate, Sales $697.00K Down From $3.33M YoY

RBC Capital Reiterates Outperform on MeiraGTx Hldgs, Maintains $11 Price Target

Recent Analyst Ratings for
$MGTX

$MGTX
Press Releases

$MGTX
Analyst Ratings

$MGTX
Leadership Updates

$MGTX
Insider Trading

$MGTX
Large Ownership Changes

$MGTX
SEC Filings

$MGTX
Financials

$MGTX
Insider Purchases

$MGTX
Market Insights